 | This is a user sandbox of JMargiott. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
Mechanism of Action
editAtazanavir binds to the active site HIV protease and prevents it from cleaving the pro-form of viral proteins into the working machinery of the virus. [1] If the HIV protease enzyme does not work, the virus is not infectious, and no mature virions are made. [2] The azapeptide drug was designed as an analog of the peptide chain substrate that HIV protease would cleave normally into active viral proteins. More specifically, atazanavir is a structural analog of the transition state during which the bond between a phenylalanine and proline is broken. [3] Humans do not have any enzymes that break bonds between phenylalanine and proline, so this drug will not target human enzymes.
- ^ https://www.drugbank.ca/drugs/DB01072
- ^ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280500/
- ^ Graziani, Amy L (June 17, 2014). "HIV protease inhibitors". UpToDate.